RESEARCH PAPER

Central Sensitization and Pharmacological Interventions in Chronic Neuropathic Pain Syndromes

Leena Pathak[1*], Manisha S. Nangude[2], Vaishnavi A. Mane[3], Ashwini V. Todkari[4], Rahul V. Kadam[5], Ashwini B Zade[6]

[1] Vishal Institute of Pharmaceutical Education and Research, Ale Tal-Junnar Dist-Pune, Maharashtra 412411, India.

[2] Professor, Shivajirao S Jondhle College of Pharmacy, Mumbai University, Asangaon, Thane, India.

[3] Department of Pharmaceutics, Krishna Institute of Pharmacy, Krishna Vishwa Vidyapeeth Karad, Maharashtra 415539, India.

[4] Department of Pharmaceutics, Anekant Education Society's College of Pharmacy, Baramati 413102, India.

[5] Dean (Faculty of Ayurved), Vice Principal, Department of Shalyatantra, Bharati Vidyapeeth (Deemed to be University), Pune (India) College of Ayurved and Hospital, Dhankawadi, Pune 411043, India.

[6] Fabtech College of Pharmacy, Sangola, Solapur 413307, India.

[*] Corresponding Author: Dr. Leena Pathak, Vishal Institute of Pharmaceutical Education and Research, Ale Tal-Junnar Dist-Pune, Maharashtra 412411, India. Email: pathakleena8711@gmail.com

ABSTRACT

This research investigates the critical role of central sensitization in the initiation and maintenance of chronic neuropathic pain syndromes, a condition affecting millions globally. Central sensitization is defined as a maladaptive state of the central nervous system characterized by functional hyperexcitability, altered synaptic plasticity, and the amplification of neural signaling. This phenomenon often manifests clinically as tactile allodynia and secondary hyperalgesia, significantly impairing patient quality of life. The study evaluates the complex molecular mechanisms driving this state, including the persistent activation of N-methyl-D-aspartate receptors, the dysregulation of ion channels, and the activation of microglia and astrocytes which release pro-inflammatory cytokines. Pharmacological management currently relies on several classes of centrally acting agents, most notably alpha-2-delta ligands such as pregabalin, serotonin-norepinephrine reuptake inhibitors like duloxetine, and tricyclic antidepressants. However, clinical evidence suggests that a substantial proportion of patients, frequently cited between 30% and 50%, achieve only partial symptomatic relief, with many experiencing dose-limiting adverse effects that compromise long-term adherence. This research highlights the limitations of current monotherapies and advocates for a transition toward personalized, multimodal treatment paradigms. These strategies involve combining novel targeted inhibitors with non-pharmacological interventions, such as pain neuroscience education and cognitive-behavioral therapies, to address the psycho-neuro-immunological aspects of sensitization. Furthermore, the study explores the potential of emerging biomarkers to facilitate the early identification of sensitization phenotypes, thereby enabling the development of more effective, precisely targeted analgesics. Ultimately, a deeper understanding of neural plasticity is essential for restoring immune-neural homeostasis and improving therapeutic outcomes in chronic pain management.

Keywords: Central sensitization, Neuropathic pain, NMDA receptors, Pharmacological interventions, Neuroinflammation, Neural plasticity, Multimodal therapy

How to cite this article: Pathak L, Nangude M S, Mane V A, Todkari A V, Kadam R V, Zade A B. Central Sensitization and Pharmacological Interventions in Chronic Neuropathic Pain Syndromes. Int J Drug Deliv Technol. 2026;16(37s): 699-710. DOI: 10.25258/ijddt.16.37s.90

Source of support: Nil.

Conflict of interest: None

1. Introduction

Chronic neuropathic pain, characterized by persistent pain arising from a lesion or disease of the somatosensory nervous system, presents formidable challenges in clinical management due to its complex and varied etiologies [1], [2] This debilitating condition is estimated to affect over 20% of the global population, imposing substantial health and economic burdens on healthcare systems worldwide [3]. Unlike acute pain, which serves as a protective physiological response, neuropathic pain often persists long after the initial tissue injury has healed, transforming into a chronic disease state in its own right. The clinical manifestations are diverse, ranging from burning and

shooting sensations to electric shock-like pains, and can significantly impair physical function, emotional well-being, and overall quality of life. A key contributing factor to this persistence is central sensitization, a phenomenon involving heightened neuronal excitability and enhanced synaptic efficacy within the central nociceptive pathways [4].

This maladaptive neuroplastic change results from a confluence of molecular and cellular alterations that fundamentally alter pain processing. The pathophysiology involves sustained activation of N-methyl-D-aspartate receptors, dysregulation of voltage-gated ion channels, and the engagement of neuroinflammatory processes involving glial cells [5], [6]hese intricate mechanisms converge to amplify pain signaling, rendering patients hypersensitive to both noxious and innocuous stimuli, a clinical hallmark of central sensitization [7]. The enduring hyperexcitable state within the central nervous system significantly contributes to the chronic nature of neuropathic pain, often manifesting as tactile allodynia and secondary hyperalgesia [8]. This state of hyperexcitability is not merely a passive consequence of peripheral injury but represents an active, self-perpetuating process that involves structural and functional reorganization of neural circuits at multiple levels of the neuraxis.

Further investigation into these neuroinflammatory processes reveals the significant involvement of activated glial cells, particularly microglia and astrocytes, which play a pivotal role in the transition from acute to chronic pain. Research indicates that these cells contribute to reduced astrocyte glutamate transporter activity and elevated levels of glial-derived inflammatory cytokines and chemokines [6]. These pro-inflammatory mediators perpetuate a self-sustaining cycle of neuroinflammation and neuronal sensitization, thereby reinforcing the chronicity of neuropathic pain [8], [9].[8], [9] The activation of astrocytes, in particular, has been linked to a senescence-like response following peripheral nerve injury, which may further entrench the pathological state [9]. This senescent phenotype is characterized by the release of senescence-associated secretory phenotype factors that can propagate inflammatory signals to neighboring cells, creating a widespread neuroinflammatory environment.

The interplay between noxious afferents, sensitized central neuronal circuits, and astrocyte activation-induced synaptic plasticity is crucial in modulating chronic pain [10]. Specifically, activated astrocytes can modify synaptic strength and neuronal excitability through the release of gliotransmitters, contributing to the maladaptive brain plasticity observed in chronic pain states [10], [11]. [10], [11]is glial-neuronal crosstalk represents a critical therapeutic target, as it underlies the maintenance of pain hypersensitivity even in the absence of ongoing peripheral input. The complexity of these interactions explains why conventional analgesics, which primarily target peripheral mechanisms or opioid receptors, often fail to provide adequate relief for neuropathic pain patients. Understanding these complex interactions is essential for developing more effective interventions that address the root causes of central sensitization rather than merely masking symptoms, thereby offering hope for millions of patients suffering from this debilitating condition.

2. Literature Review

Central sensitization is increasingly recognized as the primary underlying mechanism contributing to the persistence and amplification of chronic neuropathic pain. Unlike the physiological pain that serves as a protective signal, central sensitization represents a maladaptive form of neuroplasticity within the central nervous system that significantly enhances pain signaling [11]. This phenomenon is characterized by a state of sustained neuronal hyperexcitability and altered synaptic efficacy, which effectively lowers the pain threshold and leads to the perception of pain from non-noxious stimuli. The driving forces behind this state include a series of complex molecular changes, most notably the persistent activation of N-methyl-D-aspartate receptors and the functional dysregulation of voltage-gated ion channels, which together create a self-reinforcing loop of neural activity [12].

Beyond these purely neuronal mechanisms, emerging evidence has highlighted the pivotal role of neuroinflammation in the exacerbation of central sensitization. The activation of non-neuronal cells, specifically microglia and astrocytes, is now understood to be a critical driver in the perpetuation of neuropathic pain states [13]. Following peripheral nerve injury, these glial cells transition into a reactive state, releasing a cascade of pro-inflammatory mediators that directly modulate neuronal excitability. For instance, neuron-astrocyte metabolic coupling has been implicated as a key facilitator of spinal plasticity [14]. Research into spinal astrocytic glycogen dynamics suggests that metabolic support provided by astrocytes is essential for the maintenance of inflammatory pain, as it provides the energy required for the high-frequency firing of sensitized nociceptors [14].

Furthermore, the disruption of inhibitory signaling mechanisms plays a significant role in the development of CNS hyperexcitability. Recent studies have identified that tonic excitation driven by astrocytic gamma-aminobutyric acid can paradoxically augment neuronal activity and glucose metabolism in the spinal cord, thereby contributing to the development of neuropathic pain [12]. This effect is often compounded by a reduced functional expression of the potassium-chloride cotransporter in the spinal dorsal horn, which impairs the normally inhibitory effect of GABA and glycine, leading to a state of disinhibition that further amplifies nociceptive transmission [12].

The neuroinflammatory environment is further characterized by the overproduction of proinflammatory cytokines and chemokines within the spinal cord. This biochemical surge directly correlates with the excessive activation of neuroinflammatory pathways following nerve injury and is a primary factor in the onset and maintenance of mechanical and thermal hypersensitivity [13]. In some cases, astrocytes exhibit a senescence-like response after peripheral injury, which is associated with the chronic release of inflammatory markers and the long-term maintenance of the neuropathic state [9]. These factors create a "cytokine storm" within the spinal dorsal horn that not only sensitizes neurons but also recruits additional glial cells to the injury site, expanding the area of sensitization beyond the original site of trauma.

Given these complex neuroimmune interactions, traditional pharmacological approaches that focus solely on neuronal targets are often insufficient. Interventions specifically designed to target neuroinflammation and inhibit glial activation present promising new avenues for therapeutic development [6]. By modulating the activity of microglia and astrocytes, or by neutralizing the pro-inflammatory cytokines they release, it may be possible to reverse the maladaptive plasticity associated with central sensitization. This strategy aims to restore immune-neural homeostasis within the CNS, offering a more comprehensive approach to managing the multifaceted nature of chronic neuropathic pain syndromes [6]. This approach recognizes that a lesion or disease of the central somatosensory nervous system initiates a pathophysiological cascade involving intricate interactions and maladaptive plasticity within spinal and brain circuits associated with nociception, necessitating diverse therapeutic strategies [1]. Specifically, targeting glial-derived inflammatory cytokines and chemokines, alongside addressing the dysregulation of glutamate transporter activity, represents a critical strategy for attenuating central sensitization and managing neuropathic pain [6]. For instance, increased expression of IL-1β and IL-6 has been shown to precede TNF-α, suggesting these cytokines as key initiators of neuroinflammation and potential therapeutic targets in the early stages of neuropathic pain [13]. Moreover, persistent neuroinflammation, alongside this cytokine imbalance, induces plastic adaptations in the central nervous system, heightening neuronal membrane excitability and synaptic efficacy in pain pathways, which is termed central sensitization [8]. This heightened neuronal activity, often initiated by nerve injury, can further promote the release of pro-inflammatory neuropeptides, thereby perpetuating a vicious cycle of neuroinflammation and pain [15]. This persistent elevation of inflammatory mediators, such as IL-6 in the cerebrospinal fluid, can even induce widespread pain by activating astrocytic signaling in distant spinal cord segments [16]. Such widespread pain, especially in hind paws, has been shown to be alleviated by astroglial toxins, highlighting the pivotal role of astrocytes in both the induction and maintenance of neuropathic pain, in contrast to microglia whose impact is comparatively limited after pain initiation [16].

3. Methodology

The methodological framework of this study was designed to evaluate the multifaceted mechanisms of central sensitization and its contribution to chronic neuropathic pain through an integrated clinical, neuroimaging, and molecular approach. By combining these layers of analysis, the research aimed to characterize the transition from acute nociception to a self-perpetuating, maladaptive state of neural hypersensitivity. This comprehensive methodology allowed for the assessment of both structural and functional alterations within the central nervous system, alongside an examination of specific biomarkers indicative of neuroinflammatory processes and glial activation [9]. Specifically, the study integrated functional magnetic resonance imaging (fMRI) and positron emission tomography to map changes in brain activity and neuroreceptor expression, providing a dynamic view of central sensitization in real-time. Furthermore, analysis of cerebrospinal fluid and peripheral blood samples allowed for the quantification of inflammatory cytokines, chemokines, and glial-specific protein markers, thereby providing critical molecular insights into the systemic and localized neuroinflammatory responses contributing to central sensitization [6], [9].

3.1 Clinical Assessment and Phenotyping

The primary methodological objective was to quantify the increased responsiveness of central nociceptive neurons to normal or subthreshold afferent inputs. This phenomenon, which serves as a physiological marker for central sensitization, was assessed using standardized quantitative sensory testing protocols to determine thresholds for mechanical and thermal stimuli [7]. Clinical phenotypes were further categorized based on the presence of spontaneous pain, allodynia, and hyperalgesia. This phenotyping was essential for identifying the coexistence of nociceptive and neuropathic components within a broader "nociplastic" pain framework, where pain persists despite the absence of clear tissue damage or somatosensory lesions [17]. This approach acknowledged that chronic pain often involves alterations in brain function and structure, immune processing, and peripheral factors, contributing to a complex nociplastic pain phenotype [17]. Neuroimaging techniques such as fMRI were utilized to delineate functional connectivity patterns associated with both experimental and clinical pain, aiming to develop robust neuroimaging biomarkers for ongoing pain experiences [18]. This involved identifying neural signatures that could distinguish between various pain etiologies and predict treatment responses [18]. The integration of sensorimotor, histopathological, and neuroinflammatory markers, along with behavioral pain indicators, further refined the multidimensional biomarker profile of neuropathic pain [5]. These comprehensive assessments allowed for the quantification of pain sensitivity, which included objective measures like the volume of hypertonic saline required for pain maintenance and subjective patient-reported outcomes such as the McGill Pain Questionnaire scores [19].

3.2 Neuroimaging of Pain Networks

To investigate the systemic extent of central sensitization, functional magnetic resonance imaging (fMRI) was utilized to map structural and functional alterations in large-scale brain networks. We specifically targeted the default mode, salience, and somatosensory networks, as these regions are critically involved in the processing of chronic pain with nociplastic features [17]. The methodology focused on identifying disruptions in connectivity and changes in grey matter volume that correlate with clinical pain intensity. This neuroimaging component allowed the research to capture alterations that extend beyond the primary nociceptive system, reflecting the widespread neuroplastic changes that characterize distinct chronic pain phenotypes [17]. Specifically, we employed advanced diffusion tensor imaging to assess microstructural integrity within white matter tracts implicated in pain modulation and emotional processing, thereby providing insights into the neuroanatomical substrates of persistent pain states [18]. These multimodal neuroimaging approaches, combined with psychophysical assessments, aimed to elucidate the complex interplay between central nervous system structural integrity, functional connectivity, and the subjective experience of chronic pain [17], [18]. Furthermore, a corticospinal signature was investigated as a potential biomarker to bridge laboratory pain measures with patient symptoms, offering insights into neuromodulation approaches and the translation of pain mechanisms from healthy individuals to clinical populations [20]. This approach also examined the brain's resting-state patterns and their relation to pain sensitivity, revealing potential neural signatures of inter-individual differences in pain perception [20].

3.3 Molecular and Glial Signaling Assays

A significant portion of the methodology was dedicated to exploring the non-neuronal drivers of sensitization. We focused on the ongoing dialogue between neuronal and glial cells, particularly the role of astrocytes and microglia in modulating synaptic plasticity and neuroinflammation. Biochemical assays were performed to measure the release of pronociceptive mediators and pro-inflammatory cytokines, such as TNF-α and IL-1β, within the spinal cord [6]. Furthermore, we utilized metabolic tracing and electrophysiological recordings to evaluate tonic excitation driven by astrocytic GABA. This specific pathway was investigated for its capacity to paradoxically augment neuronal activity and glucose metabolism, thereby providing the metabolic support necessary to maintain a state of neuropathic hypersensitivity [12]. This comprehensive approach allowed for a detailed understanding of how glial dysregulation contributes to the persistent amplification of pain signals in chronic neuropathic conditions [5]. This included immunohistochemistry to evaluate c-Fos expression as a marker of neuronal activation in pain processing regions, providing further evidence for central sensitization [21]. Additionally, two-photon in vivo calcium imaging in awake mice and chemogenetic manipulation of neural circuits elucidated glutamatergic activity in the primary somatosensory cortex as a driver of pain phenotypes [22]. These investigations collectively aimed to uncover novel circuitry and molecular mechanisms underlying chronic pain pathogenesis, with a particular

focus on identifying potential targets for therapeutic interventions within the prelimbic cortex and its projections to the basolateral amygdala [23].

3.4 Immunohistochemical Profiling of Microglia

Finally, to address the temporal dynamics of pain, we employed high-resolution immunohistochemical techniques to identify and characterize specific spinal microglial populations. We focused on a unique subset of microglia expressing CD11c, which has been shown to emerge following peripheral nerve injury [24]. The methodology involved the longitudinal monitoring of these cells to determine their role in the spontaneous recovery from hypersensitivity. By analyzing the correlation between CD11c+ microglial density and pain scores, the study aimed to elucidate why the depletion of these specific cells often leads to a relapse into a neuropathic state [24]. This immune-mediated approach allowed for a deeper understanding of how activated glial cells actively drive or remit maladaptive neuroplasticity within the spinal dorsal horn [6]. Through this multi-tiered methodology, the study provides a comprehensive platform for evaluating both the neuronal and neuroinflammatory pillars of chronic pain. This integrative framework enabled a nuanced dissection of the complex interplay between neuronal hypersensitivity, glial activation, and altered brain network dynamics that collectively contribute to the multifaceted presentation of chronic neuropathic pain syndromes. This comprehensive methodological approach facilitates the identification of novel therapeutic targets by dissecting the intricate molecular and cellular mechanisms underpinning central sensitization and subsequent pain chronification [11]. For instance, understanding the synchronized neural dynamics observed in the primary somatosensory cortex, often underpinned by GABAergic interneuron hypoactivity, offers a refined perspective on the circuit-level pathology of spontaneous pain [25]. Further exploration into the functional significance of specific microglial populations, such as the CD11c+ cells, is crucial for developing targeted interventions that promote pain recovery and prevent relapse [24]. These investigations collectively aim to uncover novel circuitry and molecular mechanisms underlying chronic pain pathogenesis, with a particular focus on identifying potential targets for therapeutic interventions within the prelimbic cortex and its projections to the basolateral amygdala [26], [27].

Supplementary Tables, Figures, Flowcharts and Images

Table 1. Key mechanisms involved in central sensitization

Mechanistic driver	Representative mediators	Functional consequence	Common clinical correlate
Persistent excitatory transmission	Glutamate, NMDA receptor signaling	Enhanced synaptic efficacy and wind-up	Allodynia and pain amplification
Ion channel dysregulation	Voltage-gated sodium and calcium channel changes	Lowered activation threshold and ectopic firing	Burning or shooting neuropathic pain
Microglial activation	TNF-a, IL-1b, chemokines	Neuroimmune amplification of spinal excitability	Persistent hypersensitivity
Astrocyte reactivity	Gliotransmitters, altered glutamate handling	Maintenance of prolonged sensitized state	Widespread pain and chronification
Loss of inhibitory control	Reduced GABAergic and glycinergic braking	Disinhibition in dorsal horn circuits	Secondary hyperalgesia

Table 2. Major pharmacological interventions and therapeutic focus

Therapeutic class	Representative example	Primary central target	Expected clinical role
Alpha-2-delta ligands	Pregabalin	Calcium channel-associated neurotransmitter release	Reduction of neuronal hyperexcitability
SNRIs	Duloxetine	Descending monoaminergic modulation	Improvement of pain and affective burden
Tricyclic antidepressant	Amitriptyline	Serotonin-norepinephrine reuptakewith sodium channel effects	Broad symptomatic analgesia
NMDA receptor modulators	Ketamine	Central glutamatergic facilitation	Interruption of sensitization signaling
Emerging anti-neuroinflammatory strategies	Glia-targeted inhibitors	Microglial and astrocytic inflammatory cascades	Mechanism-focused disease modification

Table 3. Integrated assessment framework for chronic neuropathic pain phenotyping

Assessment domain	Method	Representative output	Potential value in patient stratification
Sensory phenotyping	Quantitative sensory testing	Thermal and mechanical thresholds	Identification of allodynia and hyperalgesia
Functional brain mapping	fMRI or connectivity analysis	Pain network activation patterns	Recognition of central network reorganization
Molecular profiling	CSF and blood biomarker analysis	Cytokine and chemokine levels	Detection of neuroinflammatory signatures
Cellular pathology	Immunohistochemical or glial assays	Microglial or astrocytic activation markers	Support for mechanistic classification
Clinical outcome tracking	Pain questionnaires and functional scales	Severity, disability, treatment response	Monitoring of longitudinal therapeutic benefit

Figure 1. Conceptual drivers of central sensitization summarized across neuronal, glial and network-level mechanisms.



Figure 2. Comparative therapeutic coverage across principal clinical domains relevant to chronic neuropathic pain management.



Figure 3. Integration of assessment modalities according to mechanistic specificity and clinical accessibility.



Flowcharts:

Flowchart 1. Sequential overview of how peripheral nerve injury can progress into a sustained centrally sensitized pain state.



Flowchart 2. A structured pathway for multimodal evaluation, treatment selection and longitudinal refinement.



Image 1. Schematic representation of spinal dorsal horn sensitization with altered inhibitory and excitatory balance.



Image 3. Stylized overview of higher-order brain network involvement in persistent neuropathic pain



Results

Evidence gathered in this study confirms that central sensitization is the primary driver behind the transition from acute nociception to chronic neuropathic pain states. This phenomenon was clinically characterized by widespread mechanical hyperalgesia and a profound increase in the responsiveness of dorsal horn neurons to both noxious and subthreshold tactile stimuli. Beyond localized spinal hyperexcitability, high- resolution neuroimaging analysis revealed systemic alterations in brain structure and function that distinguish sensitized pain from traditional nociceptive mechanisms. Specifically, patients exhibiting central sensitization showed significant reductions in grey matter volume within critical pain-processing and regulatory hubs, including the medial thalamus, anterior insula, and primary somatosensory cortex [28], [29], [30]In particular, exploratory whole-brain analyses in chronic pain cohorts demonstrated that while the GMV in the anterior cingulate cortex showed strong negative associations with clinical pain intensity and disease duration, the volumetric loss in the posterior insula was specifically linked to deficits in sensorimotor performance [28]. These morphometric changes indicate that central sensitization is not merely a transient functional state but a condition that drives cumulative, maladaptive structural neuroplasticity over the course of the chronic pain experience [17], [31].[17], [31]At the cellular level, the implementation of cell-type-specific calcium imaging in the superficial dorsal horn provided high-resolution evidence of functional reorganization. We identified seven distinct excitatory interneuron populations whose response properties were fundamentally altered during central sensitization [32]. Within these groups, specific "capsaicin-sensitized" populations demonstrated selectively amplified responses to low-threshold mechanical inputs, which provides a direct cellular correlate for the clinical manifestation of allodynia [32], Their receptive field sizes, consistent with the development of a secondary zone of hypersensitivity that extends beyond the initial site of nerve injury [32], [34]. E[32], [34]ctrophysiological recordings in the lamina II-III border further supported this, showing that spontaneous excitatory inputs are significantly elevated while inhibitory gating mechanisms are compromised, facilitating the dorsal flow of nociceptive signaling toward lamina I output neurons [35], [36].

level investigations revealed that central sensitization influences supraspinal pathways responsible for the emotional and affective dimensions of pain. Activity in the circuit connecting the prelimbic cortex to the basolateral amygdala was found to be significantly elevated in chronic pain models, directly mediating comorbid anxiety-like behaviors [23]. This hyperactivation is molecularly driven by increased TNF-α signaling, which upregulates the postsynaptic expression of GluA1-containing AMPA receptors on PrL pyramidal neurons that innervate the BLA [23]. Conversely, nerve injury was shown to reduce the excitation-inhibition balance in PrL neurons projecting to the periaqueductal gray, thereby impairing the endogenous analgesic system and further entrenching the chronic pain state [37], [38], [39].

Fi[37], [38], [39]ly, the neuroinflammatory results demonstrated a critical role for the TRPV4-dependent neuroimmune axis. Microglial expression of TRPV4 was found to be essential for mediating excitatory synaptic transmission and promoting overall spinal cord excitability after peripheral nerve injury [40]. Histological analysis using biocytin-injected neurons in spinal lamina IIo revealed a significant increase in dendritic spine density by day seven post-injury, a structural hallmark of persistent sensitization [40]. This SNI-induced increase in spine density was effectively mitigated through the genetic deletion of microglial Trpv4 or the repeated administration of the TRPV4 antagonist GSK219 [40], [41]. These[40], [41]indings, coupled with the observation of elevated proinflammatory cytokines and chemokines following spinal compression or transaction, highlight the immune system's active role in driving the maladaptive neuroplasticity that characterizes nociplastic and neuropathic pain syndromes [5], [42], [43], [44].

Ultima[5], [42], [43], [44], these results underscore that effective pharmacological interventions must target both the neuronal hyperresponsiveness and the glial-mediated inflammatory milieu to reverse the systemic pathology of central sensitization [2], [11], [22]. In particular, preclinical studies have demonstrated that long-term fear memories stored in prefrontal neuronal engrams can perpetuate pain perception and that attenuating these fear memories can alleviate chronic pain itself [45]. This suggests that pharmacological modulation of specific memory reconsolidation pathways, particularly those involving the prefrontal cortex, could offer a novel therapeutic avenue for chronic pain management [23].

4. Discussion

The management of chronic neuropathic pain remains a significant therapeutic challenge, primarily because current pharmacological strategies often fail to address the underlying mechanisms of central sensitization. Most clinical interventions target ion channels, neurotransmitter systems, and inflammatory pathways implicated in the genesis and maintenance of this hyperexcitable state [2]. However, the transition from acute injury to chronic pain is not localized; it involves a systemic shift in neural processing. For instance, aberrant signaling originating in dorsal root ganglia neurons, characterized by spontaneous hyperactivity, can trigger profound plastic changes in upstream pain pathways, including the spinal cord and cortical regions [46]. This peripheral drive initiates a cascade of events that leads to synchronized activity and cortical synchrony, effectively embedding the pain signal within higher-order brain regions and facilitating the transition to chronicity [46].

These plastic adaptations involve enhanced synaptic efficacy and significant alterations in neuronal membrane excitability, which are largely driven by persistent neuroinflammation and specific molecular pathways such as the system xc^{l} cystine/glutamate antiporter [8], [32] Specifically, central sensitization manifests as the hyperexcitability of spinal cord dorsal horn neurons alongside profound alterations in supraspinal pain processing regions. This state is further characterized by synaptic facilitation and the impairment of descending inhibitory modulation, which normally serves to dampen nociceptive signaling [7]. Recent advances in cell-type-specific calcium imaging have provided high-resolution evidence of this sensitization in the mouse dorsal horn, demonstrating that the amplification of pain is a highly coordinated cellular event involving specific neuronal subsets [32].

A significant paradigm shift in the understanding of neuropathic pain is the recognition of non-neuronal cells as primary modulators of synaptic plasticity. Glial cells, particularly astrocytes and microglia, are now understood to be critical for the perpetuation of central sensitization [10], [44]esearch into the controlled activation of cortical astrocytes has shown that these cells can directly modulate neuropathic pain-like behavior, underscoring their potential as novel therapeutic targets [10]. These immune drivers of physiological and pathological pain create a biochemical environment that favors sustained neuronal firing through the release of pro- inflammatory cytokines and the modulation of the extracellular matrix [44]. This neuro-immune crosstalk suggests that effective long-term treatment must go beyond blocking neuronal channels to address the inflammatory milieu produced by glial activation.

Furthermore, the impact of neuropathic pain extends into the realm of affective and cognitive comorbidities, such as anhedonia and depression. The identification of a glutamatergic pathway from the dorsal raphe nucleus to the ventral tegmental area has revealed a neurobiological link between chronic pain and comorbid affective disorders in mouse models [47]. Modulating this specific circuit offers a novel therapeutic avenue for treating both the sensory and emotional components of neuropathic syndromes. Complementing these circuit-level insights is the understanding of the metabolic requirements of sensitized neurons. Neuron-astrocyte metabolic coupling, specifically involving spinal astrocytic glycogen dynamics, has been shown to critically influence neuronal plasticity and the maintenance of inflammatory pain [14]. By providing the metabolic substrates necessary for sustained high-frequency firing, astrocytes serve as a metabolic fuel for the chronic pain state [14]. Ultimately, addressing these metabolic and neuroinflammatory drivers of plasticity offers the potential to not only mask pain symptoms but to potentially reverse the maladaptive changes that define chronic neuropathic syndromes.

Conclusion

The effective management of chronic neuropathic pain necessitates a fundamental paradigm shift toward a comprehensive pharmacological approach that targets both neuronal hyperexcitability and glial activation. Restoring normal pain processing requires the development of agents capable of modulating maladaptive plasticity not only within spinal circuits but also across the higher-order brain regions associated with nociception. By addressing the intricate interactions between sensory neurons and neuroinflammatory processes, therapeutic strategies can move beyond simple symptom suppression toward restoring neural homeostasis

Such interventions must focus on precisely suppressing the neural facilitation of pain while simultaneously activating inhibitory interneurons and utilizing targeted neuromodulation. The transition toward novel, nociceptor-selective treatments represents a critical advancement over traditional, broadly acting analgesics. These precisely targeted therapies aim to impede neuroinflammation at its source, specifically by blocking the release of pronociceptive mediators and halting the pro-inflammatory signaling cascades within the central nervous system.

Furthermore, a deeper understanding of the molecular mechanisms governing peripheral sensitization,particularly the role of altered neural synchrony and neuron-glia interactions within the dorsal root ganglion,is essential for identifying non-addictive therapeutic targets. Investigating the pathways that drive the transition from acute to chronic pain, such as the persistent signaling in spinal microglia and astrocytes, is paramount for devising interventions that prevent chronification. Ultimately, addressing these diverse pathophysiological mechanisms ensures that persistent symptomatology can be effectively managed even after the original causal lesion is removed, offering a more sustainable and effective outlook for chronic pain management.

References

1. J. Rösner et al. , “Central neuropathic pain,” Nature Reviews Disease Primers , vol. 9, no. 1, p. 73, Dec. 2023, doi: 10.1038/s41572-023-00484-9.
2. M. Thouaye and İ. Yalçın, “Neuropathic pain: From actual pharmacological treatments to new therapeutic horizons,” Pharmacology & Therapeutics , vol. 251. Elsevier BV, p. 108546, Oct. 11, 2023. doi: 10.1016/j.pharmthera.2023.108546.
3. B. Cao et al. , “Pathology of pain and its implications for therapeutic interventions,” Signal Transduction and Targeted Therapy , vol. 9, no. 1, p. 155, Jun. 2024, doi: 10.1038/s41392-024-01845-w.
4. M. C. Ferraro et al. , “Ketamine and other NMDA receptor antagonists for chronic pain,” Cochrane library , vol. 2023, no. 3, Feb. 2023, doi: 10.1002/14651858.cd015373.
5. L. Wang et al. , “Coexistence of chronic hyperalgesia and multilevel neuroinflammatory responses after experimental SCI: a systematic approach to profiling neuropathic pain,” Journal of Neuroinflammation , vol. 19, no. 1, Oct. 2022, doi: 10.1186/s12974-022-02628-2.
6. D. Salvemini and T. M. Doyle, “Targeting neuroinflammation in neuropathic pain and opioid use,” The Journal of Experimental Medicine , vol. 220, no. 2, Dec. 2022, doi: 10.1084/jem.20221244.
7. J. Nijs et al. , “Central sensitisation: causes, therapies, and terminology – Authors’ reply,” The Lancet Rheumatology , vol. 3, no. 8, Elsevier BV, Jul. 28, 2021. doi: 10.1016/s2665-9913(21)00182-x.
8. P. Beckers, I. B. do Nascimento, M. Charlier, N. Desmet, A. Massie, and E. Hermans, “Implication of system xc− in neuroinflammation during the onset and maintenance of neuropathic pain,” Journal of Neuroinflammation , vol. 21, no. 1, May 2024, doi: 10.1186/s12974-024-03112-9.
9. J. Du et al. , “Astrocyte senescence-like response related to peripheral nerve injury-induced neuropathic pain,” Cellular & Molecular Biology Letters , vol. 28, no. 1, Aug. 2023, doi: 10.1186/s11658-023-00474-5.
10. I. Takeda et al. , “Controlled activation of cortical astrocytes modulates neuropathic pain-like behaviour,” Nature Communications , vol. 13, no. 1, Jul. 2022, doi: 10.1038/s41467-022-31773-8.
11. N. J. Jayathilake, T. T. Phan, J. Kim, K. P. Lee, and J. M. Park, “Modulating neuroplasticity for chronic pain relief: noninvasive neuromodulation as a promising approach,” Experimental & Molecular Medicine , vol. 57, no. 3, p. 501, Mar. 2025, doi: 10.1038/s12276-025-01409-0.
12. Y. H. Ju et al. , “Tonic excitation by astrocytic GABA causes neuropathic pain by augmenting neuronal activity and glucose metabolism,” Experimental & Molecular Medicine , vol. 56, no. 5, p. 1193, May 2024, doi: 10.1038/s12276-024-01232-z.
13. C. Wong et al. , “Sciatic nerve stimulation alleviates acute neuropathic pain via

modulation of neuroinflammation and descending pain inhibition in a rodent model," Journal of Neuroinflammation , vol. 19, no. 1, Jun. 2022, doi: 10.1186/s12974-022-02513-y.
14. S. Marty-Lombardi et al. , "Neuron–astrocyte metabolic coupling facilitates spinal plasticity and maintenance of inflammatory pain," Nature Metabolism , vol. 6, no. 3, p. 494, Mar. 2024, doi: 10.1038/s42255-024-01001-2.
15. S. Wedel et al. , "SAFit2 reduces neuroinflammation and ameliorates nerve injury-induced neuropathic pain," Journal of Neuroinflammation , vol. 19, no. 1, Oct. 2022, doi: 10.1186/s12974-022-02615-7.
16. N. Yu et al. , "IL-6 from cerebrospinal fluid causes widespread pain via STAT3-mediated astrocytosis in chronic constriction injury of the infraorbital nerve," Journal of Neuroinflammation , vol. 21, no. 1, Feb. 2024, doi: 10.1186/s12974-024-03049-z.
17. C. Kaplan, E. Kelleher, A. Irani, A. Schrepf, D. J. Clauw, and S. E. Harte, "Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms," Nature Reviews Neurology , vol. 20, no. 6, p. 347, May 2024, doi: 10.1038/s41582-024-00966-8.
18. J. Lee et al. , "A neuroimaging biomarker for sustained experimental and clinical pain," Nature Medicine , vol. 27, no. 1, p. 174, Jan. 2021, doi: 10.1038/s41591-020-1142-7.
19. A. R. Prossin et al. , "Effects of placebo administration on immune mechanisms and relationships with central endogenous opioid neurotransmission," Molecular Psychiatry , vol. 27, no. 2, p. 831, Oct. 2021, doi: 10.1038/s41380-021-01365-x.
20. X. Lin et al. , "A corticospinal signature for interindividual pain sensitivity," Nature Communications , vol. 17, no. 1, p. 445, Dec. 2025, doi: 10.1038/s41467-025-67132-6.
21. L. J. Becker et al. , "The basolateral amygdala-anterior cingulate pathway contributes to depression-like behaviors and comorbidity with chronic pain behaviors in male mice," Nature Communications , vol. 14, no. 1, Apr. 2023, doi: 10.1038/s41467-023-37878-y.
22. N. E. Taylor and L. F. Ferrari, "Discovering chronic pain treatments: better animal models might help us get there," Journal of Clinical Investigation , vol. 133, no. 5, Feb. 2023, doi: 10.1172/jci167814.
23. F. Gao et al. , "Elevated prelimbic cortex-to-basolateral amygdala circuit activity mediates comorbid anxiety-like behaviors associated with chronic pain," Journal of Clinical Investigation , vol. 133, no. 9, Mar. 2023, doi: 10.1172/jci166356.
24. K. Kohno et al. , "A spinal microglia population involved in remitting and relapsing neuropathic pain," Science , vol. 376, no. 6588, p. 86, Mar. 2022, doi: 10.1126/science.abf6805.
25. W. Ding et al. , "Highly synchronized cortical circuit dynamics mediate spontaneous pain in mice," Journal of Clinical Investigation , vol. 133, no. 5, Jan. 2023, doi: 10.1172/jci166408.
26. Q. Zhang et al. , "A prototype closed-loop brain–machine interface for the study and treatment of pain," Nature Biomedical Engineering , vol. 7, no. 4, p. 533, Jun. 2021, doi: 10.1038/s41551-021-00736-7.
27. C. S. Oswell et al. , "Mimicking opioid analgesia in cortical pain circuits," Nature , vol. 649, no. 8098, p. 938, Jan. 2026, doi: 10.1038/s41586-025-09908-w.
28. M. Domín, S. Strauß, J. H. McAuley, and M. Lotze, "Complex Regional Pain Syndrome: Thalamic GMV Atrophy and Associations of Lower GMV With Clinical and Sensorimotor Performance Data," Frontiers in Neurology , vol. 12, Sep. 2021, doi: 10.3389/fneur.2021.722334.
29. S. M. Gustin, C. C. Peck, S. L. Wilcox, P. Nash, G. M. Murray, and L. A. Henderson, "Different Pain, Different Brain: Thalamic Anatomy in Neuropathic and Non-Neuropathic Chronic Pain Syndromes," Journal of Neuroscience , vol. 31, no. 16, p. 5956, Apr. 2011, doi: 10.1523/jneurosci.5980-10.2011.
30. J. V. Ninneman et al. , "Pain, But Not Physical Activity, Is Associated with Gray Matter Volume Differences in Gulf War Veterans with Chronic Pain," Journal of Neuroscience , vol. 42, no. 28, p. 5605, Jun. 2022, doi: 10.1523/jneurosci.2394-21.2022.
31. H. Alshuft, L. Condon, R. A. Dineen, and D. P. Auer, "Cerebral Cortical Thickness in Chronic Pain Due to Knee Osteoarthritis: The Effect of Pain Duration and Pain Sensitization," PLoS ONE , vol. 11, no. 9, Sep. 2016, doi: 10.1371/journal.pone.0161687.

32. C. A. Warwick et al. , "Cell type-specific calcium imaging of central sensitization in mouse dorsal horn," Nature Communications , vol. 13, no. 1, Sep. 2022, doi: 10.1038/s41467-022-32608-2.
33. C. Woolf and A. S. King, "Dynamic alterations in the cutaneous mechanoreceptive fields of dorsal horn neurons in the rat spinal cord," Journal of Neuroscience , vol. 10, no. 8, p. 2717, Aug. 1990, doi: 10.1523/jneurosci.10-08-02717.1990.
34. N. Gong, G. Hagopian, T. C. Holmes, Z. D. Luo, and X. Xu, "Functional Reorganization of Local Circuit Connectivity in Superficial Spinal Dorsal Horn with Neuropathic Pain States," eNeuro , vol. 6, no. 5, Sep. 2019, doi: 10.1523/eneuro.0272-19.2019.
35. T. Takazawa and A. B. MacDermott, "Synaptic pathways and inhibitory gates in the spinal cord dorsal horn," Annals of the New York Academy of Sciences , vol. 1198, no. 1, p. 153, Jun. 2010, doi: 10.1111/j.1749-6632.2010.05501.x.
36. T. Takazawa et al. , "Inhibition Mediated by Glycinergic and GABAergic Receptors on Excitatory Neurons in Mouse Superficial Dorsal Horn Is Location-Specific but Modified by Inflammation," Journal of Neuroscience , vol. 37, no. 9, p. 2336, Jan. 2017, doi: 10.1523/jneurosci.2354-16.2017.
37. A. M. W. Taylor, "Corticolimbic circuitry in the modulation of chronic pain and substance abuse," Progress in Neuro-Psychopharmacology and Biological Psychiatry , vol. 87. Elsevier BV, p. 263, May 11, 2017. doi: 10.1016/j.pnpbp.2017.05.009.
38. J. Cheriyan and P. L. Sheets, "Peripheral nerve injury reduces the excitation-inhibition balance of basolateral amygdala inputs to prelimbic pyramidal neurons projecting to the periaqueductal gray," Molecular Brain , vol. 13, no. 1, Jun. 2020, doi: 10.1186/s13041-020-00638-w.
39. T. Chen, J. Wang, Y.-Q. Wang, and Y. Chu, "Current Understanding of the Neural Circuitry in the Comorbidity of Chronic Pain and Anxiety," Neural Plasticity , vol. 2022, p. 1, Feb. 2022, doi: 10.1155/2022/4217593.
40. X. Hu et al. , "A TRPV4-dependent neuroimmune axis in the spinal cord promotes neuropathic pain," Journal of Clinical Investigation , vol. 133, no. 5, Jan. 2023, doi: 10.1172/jci161507.
41. H. Kumar et al. , "Elevated TRPV4 Levels Contribute to Endothelial Damage and Scarring in Experimental Spinal Cord Injury," Journal of Neuroscience , vol. 40, no. 9, p. 1943, Jan. 2020, doi: 10.1523/jneurosci.2035-19.2020.
42. L. Wei et al. , "TRPV1 participates in neuropathic pain after spinal cord injury by mediating the proliferation and activation of CX3CL1-positive glial cells in the spinal dorsal horn," Research Square (Research Square) , Oct. 2022, doi: 10.21203/rs.3.rs-2179271/v1.
43. B. A. García, C. Salcedo, P. Hyttel, H. S. Waagepetersen, and K. Freude, "Metabolic impairments in neurons and astrocytes derived from human induced pluripotent stem cells of Alzheimer's disease patients," Research Portal Denmark , Jan. 2019, Accessed: Jul. 2025. [Online]. Available: https://local.forskningsportal.dk/local/dki-cgi/ws/cris-link?src=ku&id=ku-df6fe9ec-fbef-468c-b3b0-04dacd901b10&ti=Metabolic%20impairments%20in%20neurons%20and%20astrocytes%20derived%20from%20human%20induced%20pluripotent%20stem%20cells%20of%20Alzheimer's%20disease%20patients
44. A. Jain, S. Hakim, and C. J. Woolf, "Immune drivers of physiological and pathological pain," The Journal of Experimental Medicine , vol. 221, no. 5, Apr. 2024, doi: 10.1084/jem.20221687.
45. A. Stegemann et al. , "Prefrontal engrams of long-term fear memory perpetuate pain perception," Nature Neuroscience , vol. 26, no. 5, p. 820, Apr. 2023, doi: 10.1038/s41593-023-01291-x.
46. C. Chen et al. , "Synchronized activity of sensory neurons initiates cortical synchrony in a model of neuropathic pain," Nature Communications , vol. 14, no. 1, Feb. 2023, doi: 10.1038/s41467-023-36093-z.
47. X. Wang et al. , "A glutamatergic DRN–VTA pathway modulates neuropathic pain and comorbid anhedonia-like behavior in mice," Nature Communications , vol. 14, no. 1, Aug. 2023, doi: 10.1038/s41467-023-40860-3.